PMID- 31402331
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 2212-5353 (Electronic)
IS  - 2212-5345 (Linking)
VI  - 57
IP  - 6
DP  - 2019 Nov
TI  - Variation in interferon-gamma production between QFT-Plus and QFT-GIT assays in TB 
      contact investigation.
PG  - 561-565
LID - S2212-5345(19)30072-3 [pii]
LID - 10.1016/j.resinv.2019.07.002 [doi]
AB  - BACKGROUND: Individuals with recent contact with active tuberculosis (TB) 
      patients were screened for latent tuberculosis infection (LTBI) considering their 
      greater relative risk for developing active TB. QuantiFERON(R)-TB Gold Plus 
      (QFT-Plus) assay offers two TB-specific antigen tubes (TB1 and TB2). TB2 is 
      designed to elicit both CD4 and CD8 T-cell responses. This mechanism could lead 
      to increased sensitivity as compared to the QuantiFERON(R)-TB Gold In-Tube 
      (QFT-GIT) assay. Our objective was to compare the LTBI diagnostic capability of 
      QFT-Plus with that of QFT-GIT. METHODS: A total of 412 TB contacts (median age 44 
      years) were prospectively enrolled. We conducted both QFT-Plus and QFT-GIT assays 
      concurrently. We also analyzed production of interferon-gamma (IFN-gamma) in response to 
      TB-specific antigens. RESULTS: The positivity rates in QFT-Plus and QFT-GIT were 
      7.5% (95% confidence interval (CI), 5.4-10.5) and 5.8% (CI, 3.9-8.5), 
      respectively, showing a significant difference (P < 0.05). The median 
      (inter-quartile range [IQR]) of IFN-gamma([QFT-Plus])/IFN-gamma([QFT-GIT]) was 1.41 
      (1.00-2.00). QFT-Plus produced 1.4 times IFN-gamma. CONCLUSIONS: QFT-Plus revealed 
      significantly higher positivity rate compared with QFT-GIT, which might be 
      attributed to increased IFN-gamma production. The cut-off in both QFT-Plus and 
      QFT-GIT was 0.35 IU/mL. These effects might resulted in the higher positivity 
      rate in QFT-Plus.
CI  - Copyright (c) 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All 
      rights reserved.
FAU - Tsuyuzaki, Mizue
AU  - Tsuyuzaki M
AD  - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato 
      Mihama-ku Chiba, Chiba, 261-0002, Japan. Electronic address: 
      mi-tsuyuzaki@kenko-chiba.or.jp.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, 
      Chiba 260-8677 Japan. Electronic address: igari_h@chiba-u.jp.
FAU - Okada, Nao
AU  - Okada N
AD  - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato 
      Mihama-ku Chiba, Chiba, 261-0002, Japan. Electronic address: 
      only.keep.justwatching@gmail.com.
FAU - Suzuki, Kiminori
AU  - Suzuki K
AD  - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato 
      Mihama-ku Chiba, Chiba, 261-0002, Japan. Electronic address: 
      kimi.suzuki@nifty.com.
LA  - eng
PT  - Journal Article
DEP - 20190808
PL  - Netherlands
TA  - Respir Investig
JT  - Respiratory investigation
JID - 101581124
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Interferon-gamma Release Tests/*methods
MH  - Latent Tuberculosis/*diagnosis
MH  - Male
MH  - Tuberculin Test/*methods
OTO - NOTNLM
OT  - Contact investigation
OT  - Interferon- gamma release assay
OT  - Interferon-gamma production
OT  - Latent tuberculosis infection
EDAT- 2019/08/14 06:00
MHDA- 2020/08/05 06:00
CRDT- 2019/08/13 06:00
PHST- 2019/03/06 00:00 [received]
PHST- 2019/06/11 00:00 [revised]
PHST- 2019/07/01 00:00 [accepted]
PHST- 2019/08/14 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2019/08/13 06:00 [entrez]
AID - S2212-5345(19)30072-3 [pii]
AID - 10.1016/j.resinv.2019.07.002 [doi]
PST - ppublish
SO  - Respir Investig. 2019 Nov;57(6):561-565. doi: 10.1016/j.resinv.2019.07.002. Epub 
      2019 Aug 8.